Literature DB >> 11559645

Reducing community dyspepsia drug costs: a controlled trial.

R M Valori1, C M Brown, P Strangeways, M Bradburn.   

Abstract

BACKGROUND: Dyspepsia drug costs account for nearly 0.5% of the National Health Service budget. We hypothesised that improved management of dyspepsia would lead to reduced drug costs. AIM: To determine whether a multifaceted educational strategy for general practitioners aimed at improving quality of dyspepsia management can control dyspepsia costs without increasing demand for endoscopy.
METHODS: A multifaceted educational intervention was delivered to general practitioners in West Gloucestershire but not to those in the east of the county. Dyspepsia drug costs, the primary outcome measure, were obtained from the Prescription Pricing Authority and compared between the two sides of the county. Referral rates for endoscopy, admission to the gastrointestinal bleed unit, and delayed diagnosis of gastric cancer were secondary measures recorded in West Gloucestershire only.
RESULTS: Following the intervention, drug costs declined and then stabilised in West Gloucestershire. Drug costs peaked in the control group 15 months after those in the intervention group. Using an autoregressive integrated moving average model it was estimated the overall costs in the intervention group reduced by 57.9 pence per head of population per half year (95% confidence interval 45.8-69.9 pence/half year; p<0.0001) in comparison with the control group. This difference was maintained for three consecutive years resulting in a cumulative saving of pound1.13 million. Referral rates for upper gastrointestinal endoscopy remained stable during the study period.
CONCLUSION: A multifaceted educational intervention for general practitioners designed to improve the quality of care of patients with dyspepsia is an effective means of controlling dyspepsia drug costs without increasing demand for endoscopy.

Entities:  

Mesh:

Year:  2001        PMID: 11559645      PMCID: PMC1728459          DOI: 10.1136/gut.49.4.495

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  17 in total

Review 1.  Dyspepsia in general practice.

Authors:  C Brown; W D Rees
Journal:  BMJ       Date:  1990-03-31

2.  Problems with implementing guidelines: a randomised controlled trial of consensus management of dyspepsia.

Authors:  R H Jones; S Lydeard; J Dunleavey
Journal:  Qual Health Care       Date:  1993-12

3.  Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

Authors:  B J Marshall; J R Warren
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

4.  Retailing research: increasing the role of evidence in clinical services for childbirth.

Authors:  J Lomas
Journal:  Milbank Q       Date:  1993       Impact factor: 4.911

5.  Appropriate prescribing in asthma and its related cost in east London.

Authors:  J Naish; P Sturdy; P Toon
Journal:  BMJ       Date:  1995-01-14

6.  Endoscopic studies of dyspepsia in a general practice.

Authors:  M W Gear; R J Barnes
Journal:  Br Med J       Date:  1980-05-03

7.  Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial.

Authors:  F E Silverstein; D Y Graham; J R Senior; H W Davies; B J Struthers; R M Bittman; G S Geis
Journal:  Ann Intern Med       Date:  1995-08-15       Impact factor: 25.391

8.  Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.

Authors:  J Dent; N D Yeomans; M Mackinnon; W Reed; F M Narielvala; D J Hetzel; E Solcia; D J Shearman
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

Review 9.  A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia.

Authors:  N J Talley
Journal:  Gastroenterology       Date:  1994-05       Impact factor: 22.682

10.  Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia.

Authors:  P Bytzer; J M Hansen; O B Schaffalitzky de Muckadell
Journal:  Lancet       Date:  1994-04-02       Impact factor: 79.321

View more
  7 in total

1.  Inadequate use of acid-suppressive therapy in hospitalized patients and its implications for general practice.

Authors:  Raffaella Scagliarini; Elena Magnani; Antonino Praticò; Renato Bocchini; Paola Sambo; Paolo Pazzi
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

2.  Inappropriate prescribing of proton pump inhibitors in primary care.

Authors:  Bisanth Thushila Batuwitage; Jeremy G C Kingham; Nia Emma Morgan; Ruth Louise Bartlett
Journal:  Postgrad Med J       Date:  2007-01       Impact factor: 2.401

Review 3.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

Review 4.  Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors.

Authors:  Bjarni Thjodleifsson
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Proton pump inhibitors: potential cost reductions by applying prescribing guidelines.

Authors:  Caitriona Cahir; Tom Fahey; Lesley Tilson; Conor Teljeur; Kathleen Bennett
Journal:  BMC Health Serv Res       Date:  2012-11-19       Impact factor: 2.655

6.  Guideline Adherence in Dyspepsia Investigation and Treatment.

Authors:  Katelyn Dugan; Elizabeth Ablah; Hayrettin Okut; Sachin Srinivasan; William Salyers
Journal:  Kans J Med       Date:  2020-12-11

7.  Cost-effectiveness and Economic Benefit of Continuous Professional Development for Drug Prescribing: A Systematic Review.

Authors:  David A Cook; Christopher R Stephenson; John M Wilkinson; Stephen Maloney; Jonathan Foo
Journal:  JAMA Netw Open       Date:  2022-01-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.